Quantitative analysis by reversed-phase high-performance liquid chromatography and retinal neuroprotection after topical administration of moxonidine

• Published in: International journal of ophthalmology Vol. 13; no. 3; pp. 390 - 398
• Main Author: Zhang, Qian
• Format: Journal Article
• Language: English
• Published: China International Journal of Ophthalmology Press 18.03.2020; Press of International Journal of Ophthalmology (IJO PRESS)
• Subjects: Basic Research; moxonidine; neuroprotection; retinal ganglion cell; reversed-phase high-performance liquid chromatography; superoxide dismutase; reversed-phase high-performance liquid chromatography; moxonidine; neuroprotection; superoxide dismutase; retinal ganglion cell
• DOI: 10.18240/ijo.2020.03.04
• ISSN: 2222-3959

To determine moxonidine in aqueous humor and iris-ciliary body by reversed-phase high performance liquid chromatography (RP-HPLC), and to evaluate the retinal neuroprotective effect after topical administration with moxonidine in a high intraocular pressure (IOP) model. The eyes of albino rabbits were administered topically and ipsilaterally with 0.2% moxonidine. A RP-HPLC method was employed for the identification and quantification of moxonidine between 2 and 480min, which presented in the aqueous humor and iris-ciliary body. Flash electroretinography (F-ERG) amplitude and superoxide dismutase (SOD) level were measured between day 1 and day 15 after topical administration with moxonidine in a rabbit model of high IOP. Histological and ultrastructural observation underwent to analyze the changes of retinal morphology, the inner retinal layers (IRL) thickness, and retinal ganglion cell (RGC) counting. Moxonidine was detectable between 2 and 480min after administration, and the peak concentration developed both in the two tissues at 30min, 0.51 µg/mL in aqueous humor and 1.03 µg/g in iris-ciliary body. In comparison to control, F-ERG b-wave amplitude in moxonidine eyes were significantly differences between day 3 and day 15 ( <0.01) in the high IOP model; SOD levels were significantly higher at all time-points ( <0.01) with a maximum level of 20.29 U/mgprot at day 15; and RGCs were significantly higher ( <0.05). Moxonidine is a viable neuroprotective agent with application to high IOP model. All layers of retina, including RGC layer, retinal nerve fiber layer and INL, are more preserved after moxonidine administration. SOD plays a neuroprotective role in ocular hypertension-mediated RGC death.